rss
J Neurol Neurosurg Psychiatry 1991;54:260-265 doi:10.1136/jnnp.54.3.260
  • Research Article

Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1.

  1. R P Moseley,
  2. J C Benjamin,
  3. R D Ashpole,
  4. N M Sullivan,
  5. J A Bullimore,
  6. H B Coakham,
  7. J T Kemshead
  1. Frenchay Hospital, Bristol, UK.

      Abstract

      Seven patients with carcinomatous meningitis were administered intrathecal I-131 labelled monoclonal antibody HMFG1. Clinical responses were seen in two patients, with a long term survivor at 32 months. Aseptic meningitis occurred in 4/7 patients, but more serious toxicity was observed in the form of seizures (2/7 patients) and myelosuppression (3/7 patients). Partial obliteration of the subarachnoid space was identified as a potential problem in patients with advanced disease.

      This Article

      1. Abstract
      2. PDF

      Responses

      1. Submit a response
      2. No responses published

      Register for free content

      The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

      BMJ Careers - Latest neurology and neurosurgery jobs